Please check your internet connection and try again.
# Norepinephrine Bitartrate
## Overview
Norepinephrine is a potent catecholamine with primary alpha-1 agonist activity and moderate beta-1 agonist activity. It acts as a potent vasoconstrictor and cardiac inotrope, increasing systemic vascular resistance and blood pressure with minimal effect on heart rate in many patients.
## Primary Indications
* Severe hypotensive states (e.g., septic shock, cardiogenic shock).
* First-line vasopressor in distributive shock.
* Adjunct treatment of cardiac arrest (off-label).
## Adult Dosing
* **Initial:** 0.01 mcg/kg/min to 0.05 mcg/kg/min (or a fixed rate of 2–4 mcg/min).
* **Titration:** Titrate to achieve goal Mean Arterial Pressure (MAP), typically ≥65 mmHg.
* **Maintenance:** Usual range is 0.01 mcg/kg/min to 3 mcg/kg/min.
* **Maximum:** No strict maximum dosage exists; limited by patient response, tissue perfusion, and secondary side effects (e.g., severe vasoconstriction/tachyarrhythmias).
## Pediatric Dosing
* **Initial:** 0.05 to 0.1 mcg/kg/min.
* **Titration:** Increase by 0.05–0.1 mcg/kg/min every 5–15 minutes as needed.
* **Range:** Up to 2 mcg/kg/min commonly utilized in PICU settings.
* *Note: Dosing should always follow institutional pediatric resuscitation protocols.*
## Dose Adjustments
* **Renal/Hepatic Impairment:** No formal dose adjustments required; however, caution is advised as secondary organ failure often dictates titration needs.
* **Elderly:** Use lowest effective dose due to increased sensitivity to cardiac effects.
## Contraindications
* Hypersensitivity to norepinephrine.
* Hypotension from blood volume deficit (correct hypovolemia prior to use).
* Mesenteric or peripheral vascular thrombosis (due to severe vasoconstriction risk).
## Adverse Effects
* **Common:** Bradycardia (reflex), arrhythmias, headache, anxiety.
* **Serious:** Extravasation necrosis (use a central line to prevent permanent tissue injury), severe hypertension, peripheral ischemia/gangrene, metabolic acidosis from impaired end-organ perfusion.
## Key Drug Interactions
* **MAO Inhibitors / TCAs:** May potentiate the pressor effect, leading to severe hypertension.
* **Beta-Blockers (non-selective):** May result in unopposed alpha-mediated vasoconstriction, leading to significant increases in systemic vascular resistance.
* **General Anesthetics:** Volatile anesthetics (e.g., cyclopropane, halothane) may sensitize the myocardium to catecholamines.
## Monitoring
* **Continuous:** Continuous ECG, invasive arterial blood pressure (if possible), and central venous pressure.
* **Perfusion:** Skin perfusion, urinary output, distal pulse checks (to monitor for extravasation/ischemia).
* **Lab:** Serum lactate levels as a marker of end-organ perfusion or adequacy of resuscitation.
## Clinical Pearls
* **Administration:** Ideally administered via central venous catheter to prevent necrosis. If peripheral administration is necessary, use a large vein (antecubital or larger) and monitor closely for signs of extravasation.
* **Management of Extravasation:** If infiltration occurs, stop infusion, leave the catheter in place, and infiltrate the area with **phentolamine** (5–10 mg in 10 mL saline) locally.
* **Weaning:** Wean gradually as the patient stabilizes to avoid "rebound" hypotension.
* **Compatibility:** Highly acidic; check Y-site compatibility before co-administering other drugs.
***
*Disclaimer: This information is for educational purposes and does not replace professional clinical judgment. Always consult institutional protocols and the most recent package insert or pharmacology database (e.g., Lexicomp, Micromedex) before prescribing or administering medication.*
